tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

RNXT Stock Latest News

Is RNXT a Buy, Before Earnings?
Pre-EarningsIs RNXT a Buy, Before Earnings?
2d ago
RNXT
RenovoRx appoints Timothy Donahue to Strategic Advisory Board
PremiumThe Fly
RenovoRx appoints Timothy Donahue to Strategic Advisory Board
7d ago
RNXT
RenovoRx’s PanTheR Registry Trial: A New Frontier in Tumor Treatment
PremiumCompany Announcements
RenovoRx’s PanTheR Registry Trial: A New Frontier in Tumor Treatment
16d ago
RNXT
RenovoRx’s Innovative Approach in Pancreatic Cancer Treatment: A Clinical Study Update
PremiumCompany Announcements
RenovoRx’s Innovative Approach in Pancreatic Cancer Treatment: A Clinical Study Update
17d ago
RNXT
RenovoRx expands Scientific Advisory Board with appointment of Baere
PremiumThe Fly
RenovoRx expands Scientific Advisory Board with appointment of Baere
1M ago
RNXT
RenovoRx announces first patient procedure completed in PanTheR study
PremiumThe FlyRenovoRx announces first patient procedure completed in PanTheR study
2M ago
RNXT
RenovoRx’s Earnings Call: Positive Outlook Amid Growth
Premium
Company Announcements
RenovoRx’s Earnings Call: Positive Outlook Amid Growth
2M ago
RNXT
Buy Rating Affirmed for RenovoRx Amid Promising Phase 3 Study Progress and Potential Stock Catalyst
Premium
Ratings
Buy Rating Affirmed for RenovoRx Amid Promising Phase 3 Study Progress and Potential Stock Catalyst
3M ago
RNXT
RenovoRx’s Promising Product Launch and Strategic Expansion Drive Buy Rating
PremiumRatings
RenovoRx’s Promising Product Launch and Strategic Expansion Drive Buy Rating
3M ago
RNXT
RenovoRx’s PanTheR Registry Trial: A Promising Update for Investors
PremiumCompany Announcements
RenovoRx’s PanTheR Registry Trial: A Promising Update for Investors
3M ago
RNXT
RenovoRx Reports Revenue Growth and Trial Progress
PremiumCompany Announcements
RenovoRx Reports Revenue Growth and Trial Progress
3M ago
RNXT
RenovoRx Reports Strong Q2 2025 Revenue Growth
PremiumCompany Announcements
RenovoRx Reports Strong Q2 2025 Revenue Growth
3M ago
8K
RNXT
Meet RenovoRx: Fly exclusive interview with CEO Shaun Bagai
PremiumThe FlyMeet RenovoRx: Fly exclusive interview with CEO Shaun Bagai
3M ago
RNXT
Phase 3 TIGeR-PaC Trial progressing well, RenovoRx CEO says
Premium
The Fly
Phase 3 TIGeR-PaC Trial progressing well, RenovoRx CEO says
3M ago
RNXT
RenovoRx CEO sees disconnect with Wall Street, believes shares undervalued
Premium
The Fly
RenovoRx CEO sees disconnect with Wall Street, believes shares undervalued
3M ago
RNXT
RenovoRx not far from driving revenue to cover cash burn, CEO says
PremiumThe Fly
RenovoRx not far from driving revenue to cover cash burn, CEO says
3M ago
RNXT
RenovoRx expands commercialization for RenovoCath, announces leadership hire
PremiumThe Fly
RenovoRx expands commercialization for RenovoCath, announces leadership hire
3M ago
RNXT
RenovoRx Stockholders Approve Key Proposals at Annual Meeting
PremiumCompany Announcements
RenovoRx Stockholders Approve Key Proposals at Annual Meeting
5M ago
8K
RNXT
RenovoRx price target raised to $11.50 from $11 at Ascendiant
PremiumThe Fly
RenovoRx price target raised to $11.50 from $11 at Ascendiant
5M ago
RNXT
RenovoRx Buy Rating: Promising RenovoCath Adoption and TIGeR-PaC Study Progress Drive Positive Outlook
PremiumRatingsRenovoRx Buy Rating: Promising RenovoCath Adoption and TIGeR-PaC Study Progress Drive Positive Outlook
6M ago
RNXT
RenovoRx’s Innovative Drug Delivery and Promising Clinical Trials Earn a Buy Rating
Premium
Ratings
RenovoRx’s Innovative Drug Delivery and Promising Clinical Trials Earn a Buy Rating
6M ago
RNXT
RenovoRx Earnings Call: Positive Outlook Amid Growth
Premium
Company Announcements
RenovoRx Earnings Call: Positive Outlook Amid Growth
6M ago
RNXT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >